Organovo could sell 4 million shares through at-the-market agreement

JMP Securities sells common shares to fund general corporate purposes

By Devika Patel

Knoxville, Tenn., Nov. 27 - Organovo Holdings, Inc. negotiated an at-the-market program to sell 4 million common shares on Nov. 27, according to an 8-K filed Wednesday with the Securities and Exchange Commission.

JMP Securities LLC, the distribution agent, will be paid a 3% commission.

Proceeds will be used for general corporate purposes, including research and development programs, preclinical or clinical studies, development and commercialization of products and the potential acquisition of complementary businesses, products or technologies.

Based in San Diego, Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.